KetoSwiss secures capital increase of 4 million dollars
KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based startup develops products to alleviate neurological diseases such as migraines and brain ageing. KetoSwiss is now preparing to enter the US market in the first half of 2023 in addition to advancing clinical trials.
Our brain needs energy. KetoSwiss develops “brain fuels” (img: Screenshot of video from KetoSwiss)
KetoSwiss has raised a total of 4 million US dollars as part of a pre-Series A financing round. The Basel-based startup specializes in the area of brain metabolism and the role ketones play in this. With MigraKet, its first medical product under the Brain Ritual brand, KetoSwiss is seeking to support the fight against migraines.
Ketones or ketone bodies are the breakdown products of fat metabolism. If body cells do not receive enough glucose over a longer period of time, for example when starving or on a ketogenic diet, the body burns fat instead of glucose. The ketones produced in the kidneys can be used by the cells to meet their energy needs and heal inflammation.
Market launch in USA
According to an article on startupticker.ch, KetoSwiss will use the fresh capital to prepare for the market launch of its Brain Ritual brand in the USA in the first half of 2023 and is expanding the US-based arm of the company. In addition, the startup is keen to achieve further R&D and clinical trial milestones. For example, the effects of MigraKet on brain function as well as on depression and other mental illnesses are to be examined.
The financing round was led by the North American William K. Karren Foundation, which supports research into neuropsychiatric disorders. Other investors involved include the venture capital firm R42 and the venture capital fund Healthspan Capital, both of which are based in the USA. They invest in biotechnology for longevity and regenerative medicine.
Basel Area Business & Innovation, the investment and innovation promotion agency, supported the startup via its Venture Mentoring program.
Share this article
You may also be interested in
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More
RocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...Read More
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...Read More
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...Read More